Product Expansion Capitalize on Amnio Technology's history of expanding its PalinGen membrane line and InovōFlo offerings to position complementary regenerative allograft solutions to healthcare providers, hospitals, and surgical centers seeking advanced amniotic tissue therapies.

Regenerative Market Target growth in regenerative medicine by aligning sales efforts with Amnio Technology’s focus on amniotic tissue allografts, leveraging their established product families to pursue clinics and researchers investing in quality-of-life regenerative therapies.

Healthcare Reimbursement Leverage past HCPCS coding achievements to differentiate offerings with clear reimbursement pathways, assisting customers in adopting PalinGen and ProMatrX products through established payer strategies and potential contract negotiations.

Strategic Partnerships Position partnerships with hospitals, academic centers, and research consortia to expand adoption of PalinGen and related membranes, using Amnio Technology’s proven product launches and distribution capabilities as credibility signals.

SMB-Network Engage mid-market and small-to-medium clinics and tissue banks that align with Amnio Technology’s company size and revenue profile, offering scalable solutions, training, and support to accelerate adoption of new membranes and regenerative products.